Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)


Por: Capdevila, J, Hernando, J, Molina-Cerrillo, J, Viñuales, MB, Garcia-Carbonero, R, Teulé, A, Custodio, A, Jimenez-Fonseca, P, Lopez, C, Hierro, C, Carmona-Bayonas, A, Alonso, V, Llanos, M, Sevilla, I, García-Alvarez, A, Alonso-Gordoa, T, Jiménez, IG, Anton-Pascual, B, Sánchez, AM and Grande, E

Publicada: 14 nov 2025
Resumen:
Purpose: Multikinase inhibitors have shown efficacy in endocrine neoplasms, and synergism with immune checkpoint inhibitors has been noted in other tumors.Patients and Methods: This is a prospective, multicenter, open-label, Simon two-stage optimal design, phase II study including patients with advanced and refractory endocrine and neuroendocrine neoplasms in six cohorts: lung well-differentiated neuroendocrine tumors, anaplastic thyroid cancer (ATC), adrenocortical carcinoma (ACC), pheochromocytoma/paraganglioma (PPGL), well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET), and grade 3 extrapulmonary neuroendocrine neoplasms. Patients received atezolizumab 1,200 mg intravenously every 3 weeks plus cabozantinib 40 mg/day orally until disease progression or unacceptable toxicity. The primary objective was the overall response rate (ORR) by RECIST 1.1.Results: From October 2020 to December 2022, 93 patients were included. The ORR was 14.3% [95% confidence interval (CI), 1.8-42.8] in ATC (N = 14); 8.3% (95% CI, 1.0-27.0) in ACC (N = 24); 15.4% (95% CI, 1.9-45.5) in PPGL (N = 13), and 16.7% (95% CI, 4.7-37.4) in GEP-NET (N = 24). Lung well-differentiated neuroendocrine tumors and grade 3 extrapulmonary neuroendocrine neoplasms had no responses. The duration of response was 20.4 months in ATC, 13.1 months in ACC, 12.2 months in PPGL, and 15.8 months in GEP-NET. Survival rates at 12 months in ATC and ACC were 47.6% and 47.6%, respectively. No unexpected toxicity was observed.Conclusions: Cabozantinib and atezolizumab were safely administered and showed promising ORR, and preliminary long-term survival rates were observed in aggressive and pretreated ACC and ATC, which warrants further investigation.

Filiaciones:
Capdevila, J:
 Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

Hernando, J:
 Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

Molina-Cerrillo, J:
 Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain

Viñuales, MB:
 Univ Hosp Virgen Rocio, Med Oncol Dept, Inst Biomed Sevilla IBIS, Seville, Spain

Garcia-Carbonero, R:
 UCM, Hosp Univ 12 Octubre, Imas12, Med Oncol Dept,Fac Med, Madrid, Spain

Teulé, A:
 Inst Catala Oncol ICO IDIBELL, Med Oncol Dept, Barcelona, Spain

Custodio, A:
 Hosp Univ La Paz, Med Oncol Dept, IdiPAZ, Madrid, Spain

Jimenez-Fonseca, P:
 Hosp Univ Cent Asturias, Med Oncol Dept, ISPA, Oviedo, Spain

Lopez, C:
 Hosp Univ Marques de Valdecilla, Med Oncol Dept, IDIVAL, Santander, Spain

:
 Catalan Inst Oncol ICO Badalona, Badalona Appl Res Grp Oncol B ARGO, Med Oncol Dept, Badalona, Spain

Carmona-Bayonas, A:
 UMI, Hosp Univ Morales Meseguer, IMIB, Hematol & Med Oncol Dept, Murcia, Spain

Alonso, V:
 Hosp Univ Miguel Servet, Med Oncol Dept, Inst Aragones Invest Sanitaria, Zaragoza, Spain

Llanos, M:
 Hosp Univ Canarias, Med Oncol Dept, San Cristobal De La Lagun, Spain

Sevilla, I:
 Hosp Univ Reg & Virgen Victoria Malaga, Med Oncol Dept, Invest Clin & Traslac Canc, Inst Invest Biomed Malaga IBIMA, Malaga, Spain

García-Alvarez, A:
 Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

Alonso-Gordoa, T:
 Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain

Jiménez, IG:
 Univ Hosp Virgen Rocio, Med Oncol Dept, Inst Biomed Sevilla IBIS, Seville, Spain

Anton-Pascual, B:
 Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain

Sánchez, AM:
 UCM, Hosp Univ 12 Octubre, Imas12, Med Oncol Dept,Fac Med, Madrid, Spain

Grande, E:
 MD Anderson Canc Ctr Madrid, Med Oncol Dept, C Arturo Soria 270, Madrid 28033, Spain
ISSN: 10780432





Clinical Cancer Research
Editorial
American Association for Cancer Research, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 31 Número: 22
Páginas: 4655-4663
WOS Id: 001616051300007
ID de PubMed: 40938918
imagen Green Submitted, hybrid

MÉTRICAS